People: MDxHealth SA (MDXH.BR)

MDXH.BR on Brussels Stock Exchange

4.00EUR
19 Sep 2014
Price Change (% chg)

€0.04 (+1.09%)
Prev Close
€3.96
Open
€4.01
Day's High
€4.07
Day's Low
€3.97
Volume
48,623
Avg. Vol
70,267
52-wk High
€5.29
52-wk Low
€2.65

Search Stocks

Summary

Name Age Since Current Position

Edward Erickson

68 2010 Chairman, Non-Executive Independent Director

Jan Groen

2010 Chief Executive Officer, Executive Director

Joseph Sollee

48 2010 Executive Vice President - Corporate Development and Legal Affairs

Christopher Thibodeau

42 2010 Executive Vice President of Commercial Operations

Wim van Criekinge

Chief Scientific Officer

Francis Ota

60 Executive Vice President - Finance

Miriam Reyes

Vice President - Laboratory Operations

Joseph Bigley

Vice President - Clinical Affairs

Ming-Chou Lee

Vice President - Product Development

Rudi Marien

69 2011 Non-Executive Director, representing Gengest BVBA

Rudi Pauwels

52 2013 Independent Director

R. Devenyns

48 2011 Non-Executive Independent Director

Mark Myslinski

58 2010 Non-Executive Independent Director

Biographies

Name Description

Edward Erickson

Mr. Edward L. Erickson has been Chairman and Non-Executive Independent Director of MDxHealth SA, since May 28, 2010. He currently serves as President, Director and Chief Executive Officer (CEO) of Saladax Biomedical, Inc., a privately-owned diagnostic company that develops and commercializes assays for measuring therapeutic drug levels in patients. Prior to joining Saladax, he served as President and CEO of BioNanomatrix, Inc., a private genomics company developing and commercializing proprietary DNA analysis systems. Previously, he was the Chairman, President and CEO of Cellatope Corporation, a private company developing diagnostic products in the field of autoimmune diseases. Prior to that, he served in top leadership roles, including president, CEO and/or chairman, of three venture-capital backed medical products companies, Immunicon, DepoTech and Cholestech, which completed initial public offerings under his leadership. Earlier in his career, he held senior executive positions at The Ares-Serono Group and Amersham International. Mr. Erickson is also Director of Metabolon. He holds a Masters of Business Administration from the Harvard Graduate School of Business Administration and Bachelor of Science and Master of Science degrees from the Illinois Institute of Technology. He is Member of the Company's Nomination and Remuneration Committee and the Audit Committee.

Jan Groen

Dr. Jan Groen, Ph.D., has been Chief Executive Officer and Executive Director of MDxHealth SA since April 26, 2010. He has experience in the clinical diagnostic industry, with a focus on emerging technologies, product development and commercialization. Dr. Groen previously served as President of Agendia Inc. and Chief Operating Officer of Agendia BV and was responsible for United States and European diagnostic operations. Prior to this, he served as Vice President of research and development at Focus Diagnostics Inc. Dr. Groen has held management and scientific positions at ViroClinics BV, the Erasmus Medical Center and Akzo-Nobel. He is Supervisory Board Member of IBL International BV. He holds a Doctorate in Philosophy degree from Erasmus University Rotterdam.

Joseph Sollee

Mr. Joseph (Joe) Sollee is Executive Vice President - Corporate Development and Legal Affairs of MDxHealth SA. He has provided legal counsel to MDxHealth since its inception in 2003, and in April 2008 joined the management team. Prior to joining the Company, Mr. Sollee served as Special Counsel with the law firm of Kennedy Covington (now K&L Gates), where he led the Life Sciences Practice Group. Mr. Sollee has more than 15 years of experience in the biotech industry, and has held senior legal and management positions at Triangle Pharmaceuticals and TherapyEdge. In addition, he has practiced as a corporate attorney in the Washington D.C. legal firm Swidler & Berlin and as an investment banker at Smith Barney in New York. Mr. Sollee received a Juris Doctorate in Law and a Master’s degree in International & Comparative Law from Duke University, a Bachelor of Arts degree from Harvard University, and has been awarded New York, Washington D.C. and North Carolina legal bar certifications.

Christopher Thibodeau

Mr. Christopher (Chris) Thibodeau has served as Executive Vice President of Commercial Operations of MDxHealth SA since September 28, 2010. As Vice President Commercial Operations, he is responsible for developing and executing the Company's key strategic sales & marketing and business development initiatives. Prior to joining the Company he served as Senior Director of Marketing at Agendia Inc., Vice President of Sales and Marketing for Numira Biosciences, National Director of Sales US LABS; and a number of sales and marketing management roles at Ventana Medical. Mr. Thibodeau holds a Bachelor of Science degree from the East Stroudsburg University in Pennsylvania and studied French at the Faculte des Lettres in Nancy, France.

Wim van Criekinge

Dr. Wim van Criekinge, Ph.D., has served as Chief Scientific Officer of MDxHealth SA, representing Bioinformatrix bvba. He joined the Company in August 2005. Dr. Van Criekinge is a specialist in bioinformatics. He is a part-time professor at the University of Ghent where he is head of the laboratory for computational genomics and bioinformatics (Biobix) in the department of molecular biotechnology. In 1997, he was co-founder and a director of Devgen. He graduated in 1994 as a Chemical Engineer from Universiteit Gent, Belgium, where he earned his Doctorate in Philosophy in Molecular Biology in 1998.

Francis Ota

Mr. Francis Ota is Executive Vice President - Finance of MDxHealth SA. He served as a Senior Finance Executive with a number of healthcare companies in the United States. He recently served as CFO of Captek Holdings, a specialty pharmaceutical company. Prior to that, he was Senior Director of Finance at Focus Diagnostics, Inc. a CLIA service laboratory acquired by Quest Diagnostics in 2006. Mr. Ota also held senior finance roles with Medtronic and Hewlett Packard. He earned a Master in Business Administration (MBA) from the Haas School of Business, University of California, Berkeley, and a Bachelor of Science in Finance and International Business from Leeds School of Business, University of Colorado, Boulder.

Miriam Reyes

Ms. Miriam Reyes has served as Vice President - Laboratory Operations of MDxHealth SA. She has over 12 years of experience in molecular diagnostics, specifically focused on R&D and lab operations. As Vice President of Laboratory Operations, she is responsible for MDxHealth CLIA lab operations in the United States. Previously, Ms. Reyes was Director Lab Operations at Agendia and she built the CLIA lab for the Agendia's MammaPrint breast cancer test. Prior to Agendia, she held various laboratory positions at US Labs, Combimatrix Molecular Diagnostics and IBIS Biosciences. She is a certified laboratory specialist in molecular biology; she holds a bachelor degree in science as well as a MBA degree in healthcare from the University of California in Irvine.

Joseph Bigley

Mr. Joseph Bigley has served as Vice President - Clinical Affairs of MDxHealth SA. He joined the Company at inception from Tibotec-Virco where he was Director Oncology Clinical Research since January 2001. Prior to Tibotec-Virco, Mr. Bigley was Director Clinical Operations and Associate Clinical Director of Oncology at Triangle Pharmaceuticals. Mr. Bigley held various clinical R&D positions within Burroughs Wellcome and Glaxo Wellcome, including Head of the Experimental Oncology Section and Senior Manager of the HIV program development. He worked for Hoffmann-La Roche in the areas of preclinical cancer and viral drug discovery and clinical research. He is Member of the American Association for Clinical Research (AACR) and the American Society of Clinical Oncology (ASCO). Mr. Bigley holds a MSc. degree from Fairleigh Dickinson University in Rutherford, New Jersey, United States.

Ming-Chou Lee

Dr. Ming-Chou Lee, Ph.D., is Vice President - Product Development of MDxHealth SA. Dr. Ming-Chou Lee has over 25 years of experience in molecular diagnostic product development for CLIA labs as well as IVD companies. In his previous position he was Senior Director of Assay Development at Roka Biosciences in San Diego. Prior to that he was the Vice President of Assay development at PrimeraDx in Boston. He also held senior R&D positions at Focus Diagnostics and Beckman Coulter. He holds a Doctorate in Philosophy in Molecular Biology from the University of Alabama in Birmingham and a Master of Science in Microbiology from Texas Tech.

Rudi Marien

Mr. Rudi Marien has served as Non-Executive Director, representing Gengest BVBA, of MDxHealth SA since 2011. He is Vice President of Cerba European Lab and President and Managing Director of Gengest BVBA and Biovest CVA. Through his management company, Gengest BVBA, Mr. Marien has mandates in different stock-listed and private biotech companies (BioCartis NV, Devgen NV, Quest For Growth NV, Actogenix NV, Pharmaneuroboost NV, and Oystershell NV). Mr. Marien was co-founder, reference shareholder and Chairman of Innogenetics, and has been the founder, shareholder and Managing Director of several clinical reference laboratories. He was also founder, shareholder and Managing Director of the Barc Group. He holds a degree in Pharmaceutical Sciences from the University of Gent, and is specialized in clinical biology. He is Member of the Company's Nomination and Remuneration Committee.

Rudi Pauwels

Dr. Rudi Pauwels has served as an Independent Director of MDxHealth SA since June 18, 2013. Dr. Pauwels is a serial entrepreneur who co-founded several European biotech companies, including Tibotec Virco, Galapagos Genomics, Biocartis and MDxHealth. Dr. Pauwels currently serves as chairman and Chief Executive officer of Biocartis. Starting his career at the Rega Institute for Medical Research in Leuven, Dr. Pauwels pioneered the development of novel anti-HIV treatments and diagnostic tools that enable more personalized HIV therapy. He gained a Doctorate in Philosophy from Leuven University.

R. Devenyns

Mme. Ruth Devenyns served as Non-Executive Independent Director of MDxHealth SA since 2011. She has a Master's Degree in Applied Economics (Ghent University, 1986). She has experience in the biotechnology sector. A former analyst and investment banker, Mme. Devenyns was in charge of the venture capital activities in the sector at KBC Private Equity until end of March 2012. She was involved in several IPO’s, private placements and M&A-transactions and held various directorships including Ablynx, Applied Maths and Pronota. At KBC Private Equity she also managed various investments in agrobiotech and seed companies such as CropDesign and Ceres. In June 2012 she joined Korys, the investment structure of the Colruyt family, and became Independent Director of Euronext-listed Devgen until its acquisition by Syngenta in December 2012. Currently, Mme. Devenyns is Director at Biocartis, representing Korys, and Director of FlandersBio, the biotech sector organisation in Flanders. She is Chairman of the Company's Audit Committee.

Mark Myslinski

Mr. Mark D. Myslinski has served as Non-Executive Independent Director of MDxHealth SA since May 28, 2010. He currently serves as Chief Commercial Officer for Saladax Biomedical, Inc. Previously, Mr. Myslinski was President and Chief Executive Officer (CEO) of Rapid Pathogen Screening, Inc, Senior Vice President and General Manager of Diagnostics at Hologic Inc., CEO of RedPath Integrated Pathology, Inc, and was a Johnson & Johnson executive where his responsibilities included building a new, worldwide evidence-based medicine function for the Ortho Clinical Diagnostics, Inc. For five years, Mr. Myslinski was also General Manager of Veridex, LLC a division of Ortho Clinical Diagnostics, Inc. focused on molecular and cellular diagnostics that achieved rapid sales growth under Mr. Myslinski’s tenure. Mr. Myslinski also held executive roles in the venture-backed start-ups InterScope Technologies and Precision Therapeutics, both focused on the field of pathology with an emphasis on cancer. Mr. Myslinski holds a Masters of Business Administration from Ohio University. He is Chairman of the Company’s Remuneration and Nomination Committee.

Basic Compensation

Search Stocks